Our exploration of therapeutic agents based on the known function of KMT2C demonstrated that an LSD1 inhibitor, which is effective in a mouse model of psychiatric disorder with deficiency of another H3K4 methyltransferase gene [13], restores a specific domain of behavioral phenotype as well as transcriptomic alterations in Kmt2c+/fs mice. This evidence concerns the gene KMT2C and psychiatric disorder.